MindMed 2023 annual meeting: company slate elected, FCM nominees defeated

Definium Therapeutics, Inc.

Final voting results certified July 25, 2023; unchanged from preliminary results of June 27.
All six company board nominees elected (e.g., Robert Barrow 8.15M for vs 6.26M withheld).
All four FCM MM Holdings nominees failed; each had more withheld votes (e.g., Dr. Scott Freeman 6.02M for, 7.78M withheld).
KPMG LLP reappointed as auditor (14.86M for, 0.39M against, 1.08M abstain).
Quorum 42.3% of 38.59M outstanding shares; meeting held June 21.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Definium Therapeutics, Inc. shareholders approved Election of Directors at the 2023-07-25 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-07-25

Exact text from the filing

The Company’s six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Company’s Board of Directors (the “Board”) until the 2024 annual general meeting of shareholders (the “2024 Annual Meeting”) and until his or her successor is duly elected or qualified, by the following votes:

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Definium Therapeutics, Inc. shareholders approved Appointment of Auditor at the 2023-07-25 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-07-25

Exact text from the filing

The shareholders approved the appointment of KPMG LLP as the auditor of the Company until the close of the 2024 Annual Meeting, by the following votes:

View on SEC.gov

1181 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-034489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.